Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; Gamifan for treating hemophagocytic lymphohistiocytosis; and Kineret for the treatment of rheumatoid arthritis. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Sanofi for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone46-8697-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.05 billion
Profitability
Miscellaneous
Employees1,077
Next Earnings Date2/19/2020 (Estimated)
OptionableNot Optionable
Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Frequently Asked Questions
What is Swedish Orphan Biovitrum AB (publ)'s stock symbol?
Swedish Orphan Biovitrum AB (publ) trades on the OTCMKTS under the ticker symbol "BIOVF."
How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?
Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its earnings results on Thursday, October, 31st. The company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.24 by $0.05. The business had revenue of $305.65 million for the quarter, compared to analysts' expectations of $294.08 million. Swedish Orphan Biovitrum AB (publ) had a return on equity of 20.24% and a net margin of 21.36%. View Swedish Orphan Biovitrum AB (publ)'s Earnings History.
When is Swedish Orphan Biovitrum AB (publ)'s next earnings date?
What is the consensus analysts' recommendation for Swedish Orphan Biovitrum AB (publ)?
Has Swedish Orphan Biovitrum AB (publ) been receiving favorable news coverage?
Headlines about BIOVF stock have trended positive on Saturday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Swedish Orphan Biovitrum AB (publ) earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Swedish Orphan Biovitrum AB (publ).
Who are some of Swedish Orphan Biovitrum AB (publ)'s key competitors?
Some companies that are related to Swedish Orphan Biovitrum AB (publ) include 1933 Industries (TGIF), 21st North (ULGX), 89bio (ETNB), Abacus Health Products (ABAHF), Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acreage (ACRGF), AEGON (AGN), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), Alchemist Mining (AMS), ALGAE TEC LTD/S (ALGXY), Alliance Growers (ACG) and Almirall (LBTSF).
What other stocks do shareholders of Swedish Orphan Biovitrum AB (publ) own?
Who are Swedish Orphan Biovitrum AB (publ)'s key executives?
Swedish Orphan Biovitrum AB (publ)'s management team includes the folowing people:
- Dr. Guido Oelkers, CEO & Pres (Age 54)
- Mr. Henrik Stenqvist, Chief Financial Officer (Age 52)
- Ms. Anne Marie de Jonge Schuermans, Head of Technical Operations (Age 47)
- Ms. Paula Treutiger, Head of Communications & Investor Relations (Age 52)
- Mr. Torbjörn Hallberg, Gen. Counsel & Head of Legal Affairs (Age 50)
How do I buy shares of Swedish Orphan Biovitrum AB (publ)?
Shares of BIOVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Swedish Orphan Biovitrum AB (publ)'s stock price today?
One share of BIOVF stock can currently be purchased for approximately $16.49.
What is Swedish Orphan Biovitrum AB (publ)'s official website?
How can I contact Swedish Orphan Biovitrum AB (publ)?
Swedish Orphan Biovitrum AB (publ)'s mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company can be reached via phone at 46-8697-2000 or via email at [email protected]
MarketBeat Community Rating for Swedish Orphan Biovitrum AB (publ) (OTCMKTS BIOVF)
MarketBeat's community ratings are surveys of what our community members think about Swedish Orphan Biovitrum AB (publ) and other stocks. Vote "Outperform" if you believe BIOVF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOVF will underperform the S&P 500 over the long term. You may vote once every thirty days.
